Positive study results for Eisai-Biogen lifted prospects for its drug and one from Eli Lilly — though regulators will have to weigh the risks.
Positive study results for Eisai-Biogen lifted prospects for its drug and one from Eli Lilly — though regulators will have to weigh the risks.